Is Epidiolex a Blockbuster?
On June 25th, the FDA approved GW Pharmaceuticals’ Epidiolex (cannabidiol, or CBD) for the treatment of Lennox-Gastaut syndrome (LGS) and Dravet... In Drug Watch/ July, 2018 Epidiolex’s Benefit-Risk Profile Supports Approval for Rare Epilepsies
“Is the benefit-risk profile of cannabidiol favorable for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome... In Drug Watch/ April, 2018 Zogenix's ZX-008 Offers New Hope to Patients with Dravet Syndrome
On February 6th, Zogenix announced that the FDA had granted “breakthrough therapy” designation to ZX-008 (low-dose fenfluramine), its Phase III... In Drug Watch/ February, 2018 Acorda and Sunovion: Coming to the "Rescue" in Parkinson's Disease?
A core unmet need in Parkinson’s disease (PD) is a new way to address “off” time, a term that refers to the return of motor symptoms when a... In Drug Watch/ February, 2018 Brand Access Challenges in Parkinson’s Disease: An Early Look at Nuplazid
The late-phase Parkinson’s disease (PD) pipeline has swelled, but new drugs face a challenging U.S. access and reimbursement environment. While... In Drug Watch/ December, 2016 U.S. Approval of Nuplazid: Exploring Physicians’ Take
On April 29th, the FDA approved Acadia Pharmaceuticals’ Nuplazid (pimavanserin) for the treatment of hallucinations and delusions associated with... In Drug Watch/ May, 2016